Smart Money Is Betting Big In ALNY Options

Investors with a lot of money to spend have taken a bullish stance on Alnylam Pharmaceuticals ALNY.

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with ALNY, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 9 uncommon options trades for Alnylam Pharmaceuticals.

This isn't normal.

The overall sentiment of these big-money traders is split between 66% bullish and 33%, bearish.

Out of all of the special options we uncovered, 3 are puts, for a total amount of $89,950, and 6 are calls, for a total amount of $459,073.

What's The Price Target?

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $150.0 and $200.0 for Alnylam Pharmaceuticals, spanning the last three months.

Analyzing Volume & Open Interest

Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Alnylam Pharmaceuticals's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Alnylam Pharmaceuticals's substantial trades, within a strike price spectrum from $150.0 to $200.0 over the preceding 30 days.

Alnylam Pharmaceuticals Option Activity Analysis: Last 30 Days

Largest Options Trades Observed:

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals's Current Market Status

• Currently trading with a volume of 257,225, the ALNY's price is down by -2.3%, now at $165.44.
• RSI readings suggest the stock is currently may be oversold.
• Anticipated earnings release is in 2 days.

What The Experts Say On Alnylam Pharmaceuticals

In the last month, 5 experts released ratings on this stock with an average target price of $168.2.

• An analyst from Cantor Fitzgerald downgraded its action to Neutral with a price target of $165.
• An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $165.
• Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Alnylam Pharmaceuticals with a target price of $176.
• Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Neutral with a new price target of $165.
• An analyst from JP Morgan persists with their Neutral rating on Alnylam Pharmaceuticals, maintaining a target price of $170.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Alnylam Pharmaceuticals, Benzinga Pro gives you real-time options trades alerts.